C5 and paroxysmal nocturnal hemoglobinuria: This is well-known in paroxysmal nocturnal hemoglobinuria (PNH) in which the eculizumab treatment—a human monoclonal antibody against the C5 component of complement that blocks the terminal complement pathway—facilitates abrogate intravascular hemolysis.